METHOD FOR ADMINISTRATION

• US 20190328708A1
• Filed: 07/12/2019
• Published: 10/31/2019
• Est. Priority Date: 03/19/2012
• Status: Abandoned Application

• Current Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Original Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Inventors: Glenn, Kelli, Higgins, Brian, Nichols, Gwen, Packman, Kathryn
• Application Number:
  US16/510,256
• Publication Number:
  US 20190328708A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.

Claims

1. A method of treating a patient suffering from cancer, comprising administering to said patient a pharmaceutical composition containing as an active ingredient Compound A in an amount from about 800 mg/day to about 3000 mg/day, daily, for up to about 7 days, followed by a rest period of up to about 21 days, said administration starting on the first day of a 28 day treatment cycle.

5. The method of claim 1 wherein the treatment cycle being repeated every 28 days for up to about 12 cycles.

6. The method of claim 1 wherein Compound A is administered twice daily in equal doses.

7. The method of claim 1 wherein the cancer is colorectal cancer.

8. The method of claim 1 wherein the cancer is prostate cancer.

9. The method of claim 1 wherein the cancer is lung cancer.

10. The method of claim 1 wherein the cancer is kidney cancer.

11. The method of claim 1 wherein the cancer is breast cancer.

2. A method of treating a patient suffering from cancer, comprising administering to said patient a pharmaceutical composition containing as an active ingredient Compound A in an amount from about 800 mg/day to about 3000 mg/day, daily, for up to about 5 days, followed by a rest period of up to about 23 days, said administration starting on the first day of a 28 day treatment cycle.

3. The method of claim 2 wherein Compound A is administered in an amount from about 1000 mg/day to about 2500 mg/day.

4. The method of claim 3 wherein Compound A is administered in an amount of from about 1250 mg/day to about 1800 mg/day.